EP0463969A1 - Neue 4-Aminobuttersäurederivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneizubereitungen - Google Patents
Neue 4-Aminobuttersäurederivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneizubereitungen Download PDFInfo
- Publication number
- EP0463969A1 EP0463969A1 EP91401739A EP91401739A EP0463969A1 EP 0463969 A1 EP0463969 A1 EP 0463969A1 EP 91401739 A EP91401739 A EP 91401739A EP 91401739 A EP91401739 A EP 91401739A EP 0463969 A1 EP0463969 A1 EP 0463969A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- radical
- base
- compounds
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the invention relates to novel compounds of 4-amino butyric acid, their preparation process and the pharmaceutical preparations containing them.
- arylpropionic compounds are known in the literature, which in particular have analgesic and anti-inflammatory properties.
- Baclofen or 4-amino 3- (4-chlorophenyl) butyric acid, agonist compound of GABA B receptors used in human therapy for its antispastic properties.
- Other 4-amino 3-aryl butyric acids, in particular heteroaryl butyric compounds have also been described (J. Med. Chem. 1987, 30 , 743 - 746), showing an affinity for the GABA B receptor.
- the compounds of the present invention have, compared to the compounds of the prior art, a very selective and clearly greater affinity. In addition, some of them antagonize the excitation induced by convulsants at doses lower than that of Baclofen. Others have the property of stimulating the synthesis of cyclic AMP in the cerebral cortex, thus increasing the metabolic capacities of the brain. The intensity of this affinity for the GABA B receptor and the power of their activity allow, in human or animal therapy, the administration of lower doses of the compounds of the invention. This reduced dosage goes hand in hand with a reduction in the side effects which can be observed with less active compounds since it is generally accepted that the toxicity is not linked to the pharmacological mechanism of action, but that it essentially depends of the chemical structure of the compounds.
- small amounts of the compounds of the invention produce an effect comparable to that obtained with much larger amounts of compounds of the prior art; the risks of toxic manifestations, in particular liver, are greatly reduced.
- This advantage is particularly interesting for the fragile populations to which the compounds are addressed, generally subjects suffering from spastic disorders or elderly subjects (disease of Alzheimer's, senile lunatics or those suffering from senescent disorders), populations in which the liver functions are often already disturbed.
- the invention relates to new compounds of 4-amino butyric acid corresponding to the general formula (I): in which :
- R1 represents a hydroxy, amino, lower alkylamino or lower alkoxy group, or a halogen atom
- R2 represents a hydrogen atom, a lower alkyl radical, a lower acyl radical, or a lower alkoxycarbonyl radical
- X represents an oxygen or sulfur atom or an NH group
- Y represents a carbon, oxygen or nitrogen atom
- R′1 and R′2 identical or different represent a halogen or hydrogen atom or a lower alkyl or lower alkoxy, hydroxy, nitro radical, amino, lower alkylamino or trifluoromethyl, with the proviso that when X is an oxygen atom, Y is a carbon atom and R′1 and R2 each is a hydrogen atom, then R′ Treatment cannot represent either a hydrogen atom or a methoxy group
- Z represents an oxygen or sulfur atom or an NH group
- T represents a carbon or nitrogen atom
- R′3 and R′4 identical or different represent a radical chosen from hydrogen, halogen, lower alkyl or alkoxy, hydroxy, nitro, amino, lower alkylamino or trifluoromethyl, with the proviso that when Z is a sulfur atom, T is a carbon atom and R′3 is a hydrogen atom, R′4 cannot be a methyl group or a hydrogen, chlorine, or bromine atom, and that when Z is an oxygen atom, T is a carbon atom and R′3 is a hydrogen atom, R′4 cannot be a hydrogen atom or a methyl group,
- an aromatic radical with 6 vertices including in its carbon skeleton of 1 to 3 nitrogen atoms and attached to a benzene ring, each of these 2 rings possibly being substituted,
- the invention also extends to the process for preparing the compounds of formula (I), characterized in that a compound of formula (II) is used as starting material: in which R has the same meaning as in formula (I), that we can :
- R1 ⁇ - H in which R1 ⁇ represents an amino, lower alkylamino or lower alkoxy group, to lead to a compound of formula (I) for which R1 represents an amino, lower alkylamino or lower alkoxy group,
- the compounds of formula (I) have interesting pharmacological properties. They have a very important and selective affinity for the GABA B receptor, greater than that of the derivatives of the prior art.
- GABA B receptor antagonist activity Some of them have GABA B receptor antagonist activity and as such can be administered in the treatment of memory disorders, mental disorders of senescence, as well as in the treatment of Alzheimer's disease.
- a subject of the present invention is also pharmaceutical compositions containing the derivatives of formula (I), or one of their addition salts with a pharmaceutically acceptable acid or base, alone or in combination with one or more inert excipients or vehicles, non-toxic, pharmaceutically acceptable.
- compositions according to the invention mention may be made more particularly of those which are suitable for oral, parenteral, nasal, rectal, perlingual, ocular or pulmonary administration and in particular injectable preparations, aerosols, eye or nasal drops, simple or coated tablets, sublingual tablets, capsules, packages, suppositories, creams, ointments, dermal gels ...
- the dosage varies according to the patient's age and weight, the route of administration, the nature of the condition and the treatments. possibly associated and ranges between 1 mg and 1 gram per 24 hours.
- the starting raw materials are described in the literature or can be prepared in a similar manner.
- the infrared spectra were carried out in the form of a potassium bromide tablet containing approximately 1% of the product to be analyzed.
- Acute toxicity was assessed after oral administration in groups of 5 mice (20 ⁇ 2 grams) in increasing doses (0.05; 0.1; 0.25; 0.50; 0.75 g / kg). The animals were observed at regular intervals during the first day and daily during the two weeks following the treatment.
- the compounds of the invention antagonize the excitatory activity induced by convulsive agents in hippocampal preparations.
- the inhibition is expressed as a percentage of excitation relative to the initial rate, which makes it possible to complete an inhibitory concentration 50 (IC50).
- IC50 inhibitory concentration 50
- the compounds of the invention have an IC50 of between 5 and 20 ⁇ M, baclofen in this test has an IC50 close to 50 ⁇ M.
- test compounds are administered at a dose of 10 mg / kg intraperitoneally in the OF1 / IFFA Credo strain mouse. 24 hours after the last injection, the animals are sacrificed by freezing, the cAMP present in these cerebral structures is assayed by radioimmunology according to the Amersham method (specific binding protein). Certain compounds of the invention appear to be capable of greatly increasing the cerebral synthesis of cyclic AMP.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9008093 | 1990-06-27 | ||
FR9008093A FR2663934B1 (fr) | 1990-06-27 | 1990-06-27 | Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent. |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0463969A1 true EP0463969A1 (de) | 1992-01-02 |
EP0463969B1 EP0463969B1 (de) | 1995-02-08 |
Family
ID=9398069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91401739A Expired - Lifetime EP0463969B1 (de) | 1990-06-27 | 1991-06-27 | Neue 4-Aminobuttersäurederivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneizubereitungen |
Country Status (15)
Country | Link |
---|---|
US (2) | US5162364A (de) |
EP (1) | EP0463969B1 (de) |
JP (1) | JPH04243853A (de) |
AT (1) | ATE118213T1 (de) |
AU (1) | AU637242B2 (de) |
CA (1) | CA2045445A1 (de) |
DE (1) | DE69107250T2 (de) |
DK (1) | DK0463969T3 (de) |
ES (1) | ES2071250T3 (de) |
FR (1) | FR2663934B1 (de) |
GR (1) | GR3015796T3 (de) |
IE (1) | IE65593B1 (de) |
OA (1) | OA09373A (de) |
PT (1) | PT98100A (de) |
ZA (1) | ZA914969B (de) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994004532A1 (en) * | 1992-08-19 | 1994-03-03 | Mcneilab, Inc. | 3-oxo-pyrido(1,2-a^_)benzimidazole-4-carboxyl and 4-oxo-azepino(1,2-a^_)benzimidazole-5-carboxyl derivatives useful in treating central nervous system disorders |
FR2722192A1 (fr) * | 1994-07-06 | 1996-01-12 | Adir | Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2000057862A2 (en) * | 1999-03-25 | 2000-10-05 | Novartis Ag | Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases |
US6576626B2 (en) | 1999-12-09 | 2003-06-10 | Astrazeneca Ab | Aminopropylphosphinic acids |
US6596711B1 (en) | 1999-12-09 | 2003-07-22 | Astrazeneca Ab | (Aminopropyl)methylphosphinic acids |
US7319095B2 (en) | 1999-12-09 | 2008-01-15 | Astrazeneca Ab | Use of GABAB receptor agonists |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
EP2258357A2 (de) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
EP2275095A2 (de) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
WO2011063115A1 (en) | 2009-11-19 | 2011-05-26 | Braincells Inc. | Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis |
EP2343073A2 (de) | 2003-12-11 | 2011-07-13 | Sepracor Inc. | Kombination eines Beruhigungsmittels und eines Neurotransmittermodulators und Verfahren zur Verbesserung der Schlafqualität und Behandlung von Depressionen |
WO2011091033A1 (en) | 2010-01-20 | 2011-07-28 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2011113904A1 (en) | 2010-03-17 | 2011-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
EP2377530A2 (de) | 2005-10-21 | 2011-10-19 | Braincells, Inc. | Modulation von Neurogenese durch PDE-Hemmung |
EP3753410A2 (de) | 2010-09-28 | 2020-12-23 | The Regents Of The University Of California | Kombinationen enthaltend gaba agonisten zur behandlung von hyperglyzemie |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6489355B2 (en) * | 1993-12-01 | 2002-12-03 | Eli Lilly And Company | Methods of inhibiting the effects of amyloidogenic proteins |
AR033779A1 (es) * | 2001-06-08 | 2004-01-07 | Astrazeneca Ab | Compuestos utiles en la enfermedad de reflujo |
US7109239B2 (en) | 2003-08-20 | 2006-09-19 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
EP2354120A1 (de) | 2003-08-20 | 2011-08-10 | XenoPort, Inc. | Synthese von Acyloxyalkylcarbamat-Prodrugs und Zwischenprodukten davon |
SE0401653D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
US7812026B2 (en) | 2005-12-23 | 2010-10-12 | Astrazeneca Ab | Imidazole derivatives having a positive allosteric GABAB receptor modulator effect and methods of use |
KR20080091452A (ko) * | 2005-12-23 | 2008-10-13 | 아스트라제네카 아베 | 위장 장애의 치료를 위한 이미다졸 유도체 |
KR20080080214A (ko) * | 2005-12-23 | 2008-09-02 | 아스트라제네카 아베 | 헤테로시클릭 gaba-b 조절제 |
JP2009521427A (ja) * | 2005-12-23 | 2009-06-04 | アストラゼネカ・アクチエボラーグ | 胃食道逆流症及び過敏性腸症候群の治療のためのピラゾール |
EP1968946A4 (de) * | 2005-12-23 | 2010-05-05 | Astrazeneca Ab | Imidazole als modulatoren des gaba-b-rezeptors |
CA2651862A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
US20080262064A1 (en) * | 2007-04-18 | 2008-10-23 | Astrazeneca Ab | Novel Compounds For The Treatment Of GI Disorders 682 |
KR20100015648A (ko) * | 2007-04-18 | 2010-02-12 | 아스트라제네카 아베 | 양성 알로스테릭 gabab 수용체 조절제 효과를 갖는 크산틴 화합물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0023192A1 (de) * | 1979-07-04 | 1981-01-28 | Ciba-Geigy Ag | Cyclopeptide und pharmazeutische Präparate davon, sowie Verfahren zu ihrer Herstellung und deren Anwendung |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4940460B1 (de) * | 1971-08-28 | 1974-11-02 | ||
ZA804008B (en) * | 1979-07-04 | 1981-06-24 | Ciba Geigy | New cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture |
US4581167A (en) * | 1982-01-19 | 1986-04-08 | Research Corporation | Peptide synthesis and amino acid blocking agents |
DE3241512A1 (de) * | 1982-11-10 | 1984-05-10 | Bayer Ag, 5090 Leverkusen | Substituierte malonsaeurediamide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
JP2561478B2 (ja) * | 1986-07-22 | 1996-12-11 | 武田薬品工業株式会社 | グリセリン誘導体 |
GB8707412D0 (en) * | 1987-03-27 | 1987-04-29 | Fujisawa Pharmaceutical Co | Peptide compounds |
US5047540A (en) * | 1987-12-17 | 1991-09-10 | Shionogi & Co., Ltd. | Lipid derivatives |
-
1990
- 1990-06-27 FR FR9008093A patent/FR2663934B1/fr not_active Expired - Fee Related
-
1991
- 1991-06-11 US US07/713,760 patent/US5162364A/en not_active Expired - Fee Related
- 1991-06-25 CA CA002045445A patent/CA2045445A1/fr not_active Abandoned
- 1991-06-26 PT PT98100A patent/PT98100A/pt not_active Application Discontinuation
- 1991-06-26 AU AU79294/91A patent/AU637242B2/en not_active Ceased
- 1991-06-26 IE IE222491A patent/IE65593B1/en not_active IP Right Cessation
- 1991-06-26 JP JP3154760A patent/JPH04243853A/ja active Pending
- 1991-06-27 DE DE69107250T patent/DE69107250T2/de not_active Expired - Fee Related
- 1991-06-27 DK DK91401739.7T patent/DK0463969T3/da active
- 1991-06-27 AT AT91401739T patent/ATE118213T1/de not_active IP Right Cessation
- 1991-06-27 OA OA60029A patent/OA09373A/xx unknown
- 1991-06-27 ZA ZA914969A patent/ZA914969B/xx unknown
- 1991-06-27 EP EP91401739A patent/EP0463969B1/de not_active Expired - Lifetime
- 1991-06-27 ES ES91401739T patent/ES2071250T3/es not_active Expired - Lifetime
-
1992
- 1992-07-28 US US07/920,786 patent/US5278166A/en not_active Expired - Fee Related
-
1995
- 1995-04-17 GR GR950400926T patent/GR3015796T3/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0023192A1 (de) * | 1979-07-04 | 1981-01-28 | Ciba-Geigy Ag | Cyclopeptide und pharmazeutische Präparate davon, sowie Verfahren zu ihrer Herstellung und deren Anwendung |
Non-Patent Citations (7)
Title |
---|
CHEMICAL ABSTRACTS, vol. 54, no. 12, 25 juin 1960, colonne 12107f, Columbus, Ohio, US; V.V. PEREKALIN et al.: "Synthesis of gamma-amino acids and pyrrolidones", & ZHUR. OBSHCHEI KHIM. 29, 2905-10 (1959) * |
CHEMICAL ABSTRACTS, vol. 73, no. 15, 12 octobre 1970, page 407, résumé no. 77617w, Columbus, Ohio, US; & JP-B-45 016 692 (DAIICHI SEIYAKU) 10-06-1970 * |
CHEMICAL ABSTRACTS, vol. 82, no. 23, 9 juin 1975, page 526, résumé no. 155373r, Columbus, Ohio, US; & JP-B-49 040460 (DAIICHI SEIYAKU) 02-11-1974 * |
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 28, no. 4, 1983, pages 353-358, Paris, FR; J. MAILLARD et al.: "Synthèse d'amino-2(benzofuryl-2)-4 delta-1 pyrrolines et étude de leurs propriétés antidysrythmiques" * |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 25, no. 6, juin 1982, pages 723-730, Washington, DC, US; M.E. SAFDY et al.: "Tryptophan analogues. 1. Synthesis and antihypertensive activity of positional isomers" * |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 30, no. 4, avril 1987, pages 743-746, Washington, DC, US; P. BERTHELOT et al.: "Synthesis and pharmacological evaluation of gamma-aminobutyric acid analogues. New ligand for GABA-B sites" * |
JOURNAL OF ORGANIC CHEMISTRY, vol. 55, no. 10, 11 mai 1990, pages 3088-3097, Washington, DC, US; R.C. PETTER et al.: "Inhibition of gamma-butyrobetaine hydroxylase by cyclopropyl-substituted gamma-butyrobetaines" * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994004532A1 (en) * | 1992-08-19 | 1994-03-03 | Mcneilab, Inc. | 3-oxo-pyrido(1,2-a^_)benzimidazole-4-carboxyl and 4-oxo-azepino(1,2-a^_)benzimidazole-5-carboxyl derivatives useful in treating central nervous system disorders |
FR2722192A1 (fr) * | 1994-07-06 | 1996-01-12 | Adir | Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2000057862A2 (en) * | 1999-03-25 | 2000-10-05 | Novartis Ag | Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases |
WO2000057862A3 (en) * | 1999-03-25 | 2001-08-09 | Novartis Ag | Use of gaba-b receptor ligands for the treatment of neurodegenerative diseases |
US6576626B2 (en) | 1999-12-09 | 2003-06-10 | Astrazeneca Ab | Aminopropylphosphinic acids |
US6596711B1 (en) | 1999-12-09 | 2003-07-22 | Astrazeneca Ab | (Aminopropyl)methylphosphinic acids |
US6841698B2 (en) | 1999-12-09 | 2005-01-11 | Astrazeneca Ab | Aminopropylphosphinic acids |
US7319095B2 (en) | 1999-12-09 | 2008-01-15 | Astrazeneca Ab | Use of GABAB receptor agonists |
US7807658B2 (en) | 1999-12-09 | 2010-10-05 | Astrazeneca Ab | Use of GabaB receptor agonists |
EP2343073A2 (de) | 2003-12-11 | 2011-07-13 | Sepracor Inc. | Kombination eines Beruhigungsmittels und eines Neurotransmittermodulators und Verfahren zur Verbesserung der Schlafqualität und Behandlung von Depressionen |
EP2258358A2 (de) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
EP2258359A2 (de) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
EP2258357A2 (de) | 2005-08-26 | 2010-12-08 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
EP2275095A2 (de) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
EP2275096A2 (de) | 2005-08-26 | 2011-01-19 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
EP2377530A2 (de) | 2005-10-21 | 2011-10-19 | Braincells, Inc. | Modulation von Neurogenese durch PDE-Hemmung |
EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
EP2382975A2 (de) | 2006-05-09 | 2011-11-02 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
WO2011063115A1 (en) | 2009-11-19 | 2011-05-26 | Braincells Inc. | Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis |
WO2011091033A1 (en) | 2010-01-20 | 2011-07-28 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2011113904A1 (en) | 2010-03-17 | 2011-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
EP3753410A2 (de) | 2010-09-28 | 2020-12-23 | The Regents Of The University Of California | Kombinationen enthaltend gaba agonisten zur behandlung von hyperglyzemie |
Also Published As
Publication number | Publication date |
---|---|
ATE118213T1 (de) | 1995-02-15 |
US5278166A (en) | 1994-01-11 |
CA2045445A1 (fr) | 1991-12-28 |
FR2663934B1 (fr) | 1994-06-03 |
IE65593B1 (en) | 1995-11-01 |
FR2663934A1 (fr) | 1992-01-03 |
AU7929491A (en) | 1992-01-02 |
DK0463969T3 (da) | 1995-07-10 |
JPH04243853A (ja) | 1992-08-31 |
US5162364A (en) | 1992-11-10 |
GR3015796T3 (en) | 1995-07-31 |
OA09373A (fr) | 1992-09-15 |
EP0463969B1 (de) | 1995-02-08 |
DE69107250D1 (de) | 1995-03-23 |
ZA914969B (en) | 1992-04-29 |
IE912224A1 (en) | 1992-01-01 |
PT98100A (pt) | 1992-03-31 |
ES2071250T3 (es) | 1995-06-16 |
AU637242B2 (en) | 1993-05-20 |
DE69107250T2 (de) | 1995-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0463969B1 (de) | Neue 4-Aminobuttersäurederivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneizubereitungen | |
EP0576350B1 (de) | Verzweigte Alkylaminothiazolederivate, Verfahren zu ihrer Herstellung und pharmazeutische Zusammenstellungen die sie enthalten | |
EP0591057B1 (de) | Arylalkyl(thio)amide mit Melatonin-Rezeptor-Selektivität und Prozess zu ihrer Darstellung | |
EP0447285B1 (de) | Naphthalin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
EP0494819B1 (de) | Phenylimidazolidine, Verfahren zu deren Herstellung, deren Anwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammenstellungen | |
EP0457686B1 (de) | Neue Derivate des Aminopiperidins, Aminopyrrolidins und des Aminoperhydroazepins, Verfahren zur Herstellung und diese enthaltende Arzneimittel | |
EP0530087B1 (de) | Naphthylethylharnstoff und Naphthylethylthioharnstoff Verbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten | |
EP0656890B1 (de) | Neues verfahren zur herstellung von ergothionein | |
EP1403266B1 (de) | Verfahren zur industriellen Herstellung von Strontiumranelat und seinen Hydraten | |
EP0506539A1 (de) | Heterozyklische Alkylamide, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
EP0042781B1 (de) | 1-(4- Chinolyl), 2- oder 3- (2- oder 3-piperidyl oder pyrrolidinyl)-Äthanon oder -Propanon, Verfahren zu seiner Herstellung und seine Anwendung als Arzneimittel | |
EP0526342A1 (de) | Isochinolin-5-yl-Sulfonsäureamide, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten | |
EP0662471A2 (de) | Naphthalen-Derivate mit Affinität für Melatonin-Rezeptoren, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
EP0624575A1 (de) | Substituierte Indole und diese enthaltende Arzneimittel | |
EP0274324B1 (de) | Verfahren zur Herstellung von Thienyläthylaminen, und mittels des Verfahrens hergestellte Dithienyläthylamine | |
EP1692114B1 (de) | Neue benzimidazol- und imidazopyridinderivate und deren verwendung als medikament | |
EP0635497A2 (de) | Benzospiroalken-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
EP0452204B1 (de) | 3-Aminochroman-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
FR2722192A1 (fr) | Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP0495709A1 (de) | Aryltriazinverbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten | |
CH625795A5 (de) | ||
EP0385848A1 (de) | Benzoxazolinon-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten | |
CA2256247C (fr) | Nouveaux composes heterocycliques, leur procede de praparation et les compositions pharmaceutiques qui les contiennent | |
EP0486385A1 (de) | Imidazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende Zusammenstellungen | |
EP0527079A1 (de) | N-(Isochinolein-5-yl)-Sulfonyl Azazykloalkane, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19910704 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19940408 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 118213 Country of ref document: AT Date of ref document: 19950215 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 69107250 Country of ref document: DE Date of ref document: 19950323 |
|
ITF | It: translation for a ep patent filed |
Owner name: SOCIETA' ITALIANA BREVETTI S.P.A. |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 19950511 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2071250 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3015796 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19960416 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19960419 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 19960422 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19960531 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19960601 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 19960607 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19960618 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19960621 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 19960625 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19960626 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19960627 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19960701 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970627 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970627 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970627 Ref country code: AT Effective date: 19970627 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19970628 Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 19970628 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970630 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970630 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970630 Ref country code: BE Effective date: 19970630 |
|
BERE | Be: lapsed |
Owner name: ADIR ET CIE Effective date: 19970630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19980101 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19970627 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980227 |
|
EUG | Se: european patent has lapsed |
Ref document number: 91401739.7 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19980101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19980303 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20000301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050627 |